论文部分内容阅读
包括全球一些主要眼底病专家与会的第XXV届JulesGonin学会和第39届视网膜学会联合会议,于2006年10月15~20日在南非开普敦召开。会议交流了近两年眼底病研究的重要进展。抗血管内皮生长因子疗法,主要是玻璃体内注射ranibizumab或bevacizumab,已成为新生血管性年龄相关性黄斑变性的主流疗法。关于小规格玻璃体切除术、干涉光断层扫描等成像技术方面的改进和应用,也得到了广泛关注和讨论。
Including some of the world’s major fundopause experts attending the XXV JulesGonin Society and the 39th Retina Society joint meeting, in October 2006 15 to 20 in Cape Town, South Africa. The meeting exchanged the recent progress in fundus research. Anti-vascular endothelial growth factor therapy, mainly intravitreal injection of ranibizumab or bevacizumab, has become the mainstream of neovascular age-related macular degeneration. On the small size vitrectomy, coherence tomography and other imaging imaging technology improvements and applications, has also been widely concerned and discussed.